The field of the invention is dry powder inhalers.
Certain medicines may be inhaled in dry powder form directly into the lungs. Inhalation bypasses the digestive system and avoids any potential metabolic inactivation or destruction of the medicine by the digestive system. Inhalation can also provide very rapid onset of the effect of the medicine. Inhalation may also allow smaller doses to be used to achieve the same desired results as orally ingested medicines. In other cases, it provides a delivery technique for medicines that display unacceptable side effects when taken by other methods. In addition, inhalation also avoids the potential risks of injection to both medical care givers and patients.
Various inhaler designs have been proposed, to allow dry powder medicines to be inhaled. Most of these inhalers are metered dose inhalers or multiple dose dry powder inhalers. Metered dose inhalers dispense a suspension of powder particles in a compressed propellant gas. Multiple dose dry powder inhalers generally repeatedly dispense individual doses from a bulk powder reservoir, or from a blister disk, cassette or tape. However, certain medicines, such as certain peptides or proteins, or medicines such as vaccines, antidotes, etc., are generally taken by a patient infrequently or may even be taken only once. Metered dose inhalers and multiple dose dry powder inhalers are not intended or well designed for one-time use, to deliver a single dose. These types of inhalers are typically too bulky, costly, inefficient, or difficult to use, when only a single dose is desired, and where the inhaler can be and its drug/dose unit practically discarded after use, in an environmentally acceptable way.
Several unit dose inhalers, intended for one-time use, have been proposed. However, they have not achieved widespread use. Disadvantages remain with unit dose inhalers relating to powder storage, dose uniformity, dispersion performance, ease of use, cost, and other factors. Accordingly, there is a need for an improved inhaler for efficiently providing a single dose of a powdered drug.
It is an object of the invention to provide such an improved dry powder inhaler.
A unit dose dry powder inhaler uses a dose unit containing a single dose of a pharmaceutical powder in a blister or other sealed container. As the dose unit is moved into the inhaler, the container is automatically opened, releasing the dose of powder for inhalation. This inhaler design is simple, compact, inexpensive and yet efficient.
In one aspect, the inhaler has a dispersion chamber including one or more beads. Upon inhalation, the beads move rapidly within the dispersion chamber to help disperse the powder into air. Accordingly, the powder is effectively dispersed via air flow resulting from inspiration of the user. While preferred, the beads are not an essential element.
In another aspect, a dose unit or assembly has a tab pivotably supported within the plane of a frame. The tab is separated from the frame by a slot. A container, such as a blister containing a single dose of powder medicine has a bottom surface or base layer attached to the tab. The base layer also extends over the slot and is attached to areas of the frame. As dose unit is moved typically linearly, within the inhaler, the tab pivots out of the plane of the frame. This shears or tears open the base layer releasing the powder into the inhaler. As a result, the dose of powder remains sealed within the blister or container, until moments just before inhalation. The disadvantages of prolonged exposure of the powder to the environment, such as oxidation, particle size growth, caking, etc. are reduced or avoided. In addition, the inhaler with the dose unit is very easy to use as it requires only a single simple push-button type of movement to open the container.
Other features and advantages are described below. The invention resides as well in subcombinations of the features shown and described.
In the drawings, wherein the same reference number indicates the same element in each of the views:
As shown in
Referring now also to
Referring to
Turning now to
Referring to
In use, the inhaler 10 is typically provided within an envelope or package 11 in an assembled and ready to use condition. A dose unit assembly 36 is preinstalled within the chamber tube 18 of the housing 15, as shown in
The user then places the mouthpiece 16 into the mouth and inhales. Air flows through the chamber tube 18 entraining and carrying the powder 47 through the chamber inlet 26 and into the dispersion chamber 22. The beads 24 in the dispersion chamber 22 move rapidly within the chamber, helping to disperse the powder 47. The dispersed powder/air mixture flows out of the dispersion chamber 22 into the chamber tube 18, and into the user's lungs. Sheath air is optionally provided via sheath air passageways 20 or 21, to help reduce deposition of powder particles on or in the mouthpiece 16, or the user's mouth and throat. Improved deposition of powder 47 into the user's deep lung is achieved.
As shown in
The dose unit 36 is preferably molded of a plastics material, for ease of manufacture, and with the pivot pins 56 molded in place.
The alignment ring or sector 42 helps to center and align the dose unit 36 within the chamber tube 18. Keying features may also be provided on the dose unit 36, to ensure proper angular alignment of the dose unit 36 within the chamber tube 18, so that the lever section 52 of the tab 48 properly aligns with and contacts the tab ramp 34 during use. As shown in dotted lines in
Although the housing 15 is shown as a two-piece construction including the base plate 12 and the top plate 14, single piece or multiple piece housing designs are also feasible. In addition, while the housing 15 is described here as formed by plates 12 and 14, the housing 15 may of course have other shapes and construction characteristics. Similarly, other types of dispersion chambers, with or without beads 24, may be used. For example, dispersion chambers 22 having baffles, deflection surfaces, impellers, etc., may be substituted for the dispersion chamber 22 described above. Similarly, various mouthpiece designs and configurations may also be used. While the mouthpiece 16 and chamber tube 18 are shown in the drawings as perpendicular to the chamber tube 18, parallel/flow-through designs or other positional relationships between them may be used. These features described immediately above are not essential elements of the invention.
The specific size, shape and arrangement of various of the features shown
Thus, a novel inhaler has been shown and described. Various changes and substitutions may of course be made, without departing from the spirit and scope of the invention. The invention, therefore, should not be limited, except to the following claims, and their equivalents.
This application is a Continuation of U.S. patent application Ser. No. 11/130,959, filed May 17, 2005, and now pending, which claims priority to U.S. Provisional Application No. 60/575,138 filed May 28, 2004.
Number | Date | Country | |
---|---|---|---|
60575138 | May 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11130959 | May 2005 | US |
Child | 12476985 | US |